Innate immune control of influenza virus interspecies adaptation via IFITM3.
Animals
Humans
Membrane Proteins
/ metabolism
Immunity, Innate
RNA-Binding Proteins
/ metabolism
Mice
Mice, Knockout
Orthomyxoviridae Infections
/ immunology
Influenza, Human
/ immunology
Mice, Inbred C57BL
Influenza A virus
/ immunology
Dogs
Adaptation, Physiological
/ immunology
Virus Replication
Madin Darby Canine Kidney Cells
HEK293 Cells
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
22
08
2023
accepted:
20
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Influenza virus pandemics are caused by viruses from animal reservoirs that adapt to efficiently infect and replicate in human hosts. Here, we investigate whether Interferon-Induced Transmembrane Protein 3 (IFITM3), a host antiviral factor with known human deficiencies, plays a role in interspecies virus infection and adaptation. We find that IFITM3-deficient mice and human cells can be infected with low doses of avian influenza viruses that fail to infect WT counterparts, identifying a new role for IFITM3 in controlling the minimum infectious virus dose threshold. Remarkably, influenza viruses passaged through Ifitm3
Identifiants
pubmed: 39477971
doi: 10.1038/s41467-024-53792-3
pii: 10.1038/s41467-024-53792-3
doi:
Substances chimiques
Membrane Proteins
0
IFITM3 protein, human
0
RNA-Binding Proteins
0
fragilis protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9375Informations de copyright
© 2024. The Author(s).
Références
Bailey, E. S. et al. The continual threat of influenza virus infections at the human-animal interface: What is new from a one health perspective? Evol. Med. Public Health 2018, 192–198 (2018).
pubmed: 30210800
pmcid: 6128238
doi: 10.1093/emph/eoy013
Taubenberger, J. K. & Kash, J. C. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7, 440–451 (2010).
pubmed: 20542248
pmcid: 2892379
doi: 10.1016/j.chom.2010.05.009
Enjuanes, L. et al. Nature of viruses and pandemics: coronaviruses. Curr. Res. Immunol. 3, 151–158 (2022).
pubmed: 35966177
pmcid: 9359481
doi: 10.1016/j.crimmu.2022.08.003
Dennehy, J. J. Evolutionary ecology of virus emergence. Ann. N. Y Acad. Sci. 1389, 124–146 (2017).
pubmed: 28036113
doi: 10.1111/nyas.13304
Brass, A. L. et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139, 1243–1254 (2009).
pubmed: 20064371
pmcid: 2824905
doi: 10.1016/j.cell.2009.12.017
Yount, J. S. et al. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat. Chem. Biol. 6, 610–614 (2010).
pubmed: 20601941
pmcid: 2928251
doi: 10.1038/nchembio.405
Chesarino, N. M. et al. IFITM3 requires an amphipathic helix for antiviral activity. EMBO Rep. 18, 1740–1751 (2017).
pubmed: 28835547
pmcid: 5623871
doi: 10.15252/embr.201744100
Guo, X. et al. Interferon-induced transmembrane protein 3 blocks fusion of diverse enveloped viruses by altering mechanical properties of cell membranes. ACS Nano 15, 8155–8170 (2021).
pubmed: 33656312
pmcid: 8159881
doi: 10.1021/acsnano.0c10567
Li, K. et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 9, e1003124 (2013).
pubmed: 23358889
pmcid: 3554583
doi: 10.1371/journal.ppat.1003124
Desai, T. M. et al. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 10, e1004048 (2014).
pubmed: 24699674
pmcid: 3974867
doi: 10.1371/journal.ppat.1004048
Klein, S. et al. IFITM3 blocks influenza virus entry by sorting lipids and stabilizing hemifusion. Cell Host Microbe 31, 616–633.e620 (2023).
pubmed: 37003257
doi: 10.1016/j.chom.2023.03.005
Unali, G. et al. Interferon-inducible phospholipids govern IFITM3-dependent endosomal antiviral immunity. EMBO J. 42, e112234 (2023).
pubmed: 36970857
pmcid: 10183820
doi: 10.15252/embj.2022112234
Savidis, G. et al. The IFITMS inhibit Zika virus replication. Cell Rep. 15, 2323–2330 (2016).
pubmed: 27268505
doi: 10.1016/j.celrep.2016.05.074
Shi, G. et al. Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J. 40, e106501 (2021).
pubmed: 33270927
doi: 10.15252/embj.2020106501
Kenney, A. D. et al. Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice. EMBO Rep. 24, e56660 (2023).
pubmed: 36880581
doi: 10.15252/embr.202256660
Everitt, A. R. et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484, 519–523 (2012).
pubmed: 22446628
doi: 10.1038/nature10921
Allen, E. K. et al. SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans. Nat. Med. 23, 975–983 (2017).
pubmed: 28714988
doi: 10.1038/nm.4370
Zani, A. & Yount, J. S. Antiviral protection by IFITM3 in vivo. Curr. Clin. Microbiol. Rep. 5, 229–237 (2018).
pubmed: 30662816
doi: 10.1007/s40588-018-0103-0
Wang, Z. et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc. Natl Acad. Sci. USA 111, 769–774 (2014).
pubmed: 24367104
doi: 10.1073/pnas.1321748111
Pecoraro, V., Cuccorese, M. & Trenti, T. Genetic polymorphisms of ACE1, ACE2, IFTM3, TMPRSS2 and TNFα genes associated with susceptibility and severity of SARS-CoV-2 infection: a systematic review and meta-analysis. Clin. Exp. Med. 23, 1–14 (2023).
Bailey, C. C., Huang, I. C., Kam, C. & Farzan, M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 8, e1002909 (2012).
pubmed: 22969429
pmcid: 3435252
doi: 10.1371/journal.ppat.1002909
Kenney, A. D. et al. Influenza virus replication in cardiomyocytes drives heart dysfunction and fibrosis. Sci. Adv. 8, eabm5371 (2022).
pubmed: 35544568
pmcid: 9094651
doi: 10.1126/sciadv.abm5371
Kenney, A. D. et al. IFITM3 protects the heart during influenza virus infection. Proc. Natl Acad. Sci. USA 116, 18607–18612 (2019).
pubmed: 31451661
pmcid: 6744864
doi: 10.1073/pnas.1900784116
Zhang, Y. H. et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat. Commun. 4, 1418 (2013).
pubmed: 23361009
doi: 10.1038/ncomms2433
Zhang, Y. H. et al. Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. Aids 29, 889–894 (2015).
pubmed: 25784441
doi: 10.1097/QAD.0000000000000632
Randolph, A. G. et al. Evaluation of IFITM3 rs12252 association with severe pediatric influenza infection. J. Infect. Dis. 216, 14–21 (2017).
pubmed: 28531322
pmcid: 5853450
doi: 10.1093/infdis/jix242
Mills, T. C. et al. IFITM3 and susceptibility to respiratory viral infections in the community. J. Infect. Dis. 209, 1028–1031 (2014).
pubmed: 23997235
doi: 10.1093/infdis/jit468
Carter, T. C. et al. Pilot screening study of targeted genetic polymorphisms for association with seasonal influenza hospital admission. J. Med. Virol. 90, 436–446 (2018).
pubmed: 29053189
doi: 10.1002/jmv.24975
Sun, X. et al. Pathogenesis and transmission of genetically diverse swine-origin H3N2 variant influenza A viruses from multiple lineages isolated in the United States, 2011-2016. J. Virol. 92, e00665–18 (2018).
pubmed: 29848587
pmcid: 6069210
doi: 10.1128/JVI.00665-18
Lorbach, J. N. et al. Influenza vaccination of swine reduces public health risk at the swine-human interface. mSphere 6, e0117020 (2021).
pubmed: 34190586
doi: 10.1128/mSphere.01170-20
Meischel, T., Villalon-Letelier, F., Saunders, P. M., Reading, P. C. & Londrigan, S. L. Influenza A virus interactions with macrophages: lessons from epithelial cells. Cell Microbiol. 22, e13170 (2020).
pubmed: 31990121
doi: 10.1111/cmi.13170
Kamal, R. P., Katz, J. M. & York, I. A. Molecular determinants of influenza virus pathogenesis in mice. Curr. Top. Microbiol. Immunol. 385, 243–274 (2014).
pubmed: 25038937
pmcid: 4618372
Schoggins, J. W. Interferon-stimulated genes: what do they all do? Annu. Rev. Virol. 6, 567–584 (2019).
pubmed: 31283436
doi: 10.1146/annurev-virology-092818-015756
Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).
pubmed: 32972995
pmcid: 7857407
doi: 10.1126/science.abd4570
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
pubmed: 32972996
pmcid: 7857397
doi: 10.1126/science.abd4585
Zhou, B. et al. PB2 residue 158 is a pathogenic determinant of pandemic H1N1 and H5 influenza a viruses in mice. J. Virol. 85, 357–365 (2011).
pubmed: 20962098
doi: 10.1128/JVI.01694-10
Ilyushina, N. A. et al. Adaptation of pandemic H1N1 influenza viruses in mice. J. Virol. 84, 8607–8616 (2010).
pubmed: 20592084
pmcid: 2918990
doi: 10.1128/JVI.00159-10
Buchrieser, J. et al. IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise. Science 365, 176–180 (2019).
pubmed: 31296770
doi: 10.1126/science.aaw7733
Zani, A. et al. Interferon-induced transmembrane proteins inhibit cell fusion mediated by trophoblast syncytins. J. Biol. Chem. 294, 19844–19851 (2019).
pubmed: 31735710
doi: 10.1074/jbc.AC119.010611
Yockey, L. J. et al. Type I interferons instigate fetal demise after Zika virus infection. Sci. Immunol. 3, eaao1680 (2018).
pubmed: 29305462
pmcid: 6049088
doi: 10.1126/sciimmunol.aao1680
Smith, E. C. The not-so-infinite malleability of RNA viruses: viral and cellular determinants of RNA virus mutation rates. PLoS Pathog. 13, e1006254 (2017).
pubmed: 28448634
pmcid: 5407569
doi: 10.1371/journal.ppat.1006254
Shi, G. et al. Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. J. Clin. Invest. 132, 769–764 (2022).
Poddar, S., Hyde, J. L., Gorman, M. J., Farzan, M. & Diamond, M. S. The interferon-stimulated gene IFITM3 restricts infection and pathogenesis of arthritogenic and encephalitic alphaviruses. J. Virol. 90, 8780–8794 (2016).
pubmed: 27440901
pmcid: 5021394
doi: 10.1128/JVI.00655-16
Gorman, M. J., Poddar, S., Farzan, M. & Diamond, M. S. The interferon-stimulated gene IFITM3 restricts west Nile virus infection and pathogenesis. J. Virol. 90, 8212–8225 (2016).
pubmed: 27384652
pmcid: 5008082
doi: 10.1128/JVI.00581-16
Jabre, R., Sandekian, V. & Lemay, G. Amino acid substitutions in σ1 and μ1 outer capsid proteins are selected during mammalian reovirus adaptation to Vero cells. Virus Res. 176, 188–198 (2013).
pubmed: 23800405
doi: 10.1016/j.virusres.2013.06.007
Pérez-Cidoncha, M. et al. An unbiased genetic screen reveals the polygenic nature of the influenza virus anti-interferon response. J. Virol. 88, 4632–4646 (2014).
pubmed: 24574395
pmcid: 3993829
doi: 10.1128/JVI.00014-14
García-Sastre, A. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324–330 (1998).
pubmed: 9878611
doi: 10.1006/viro.1998.9508
Sun, X. et al. Constitutively expressed IFITM3 protein in human endothelial cells poses an early infection block to human influenza viruses. J. Virol. 90, 11157–11167 (2016).
pubmed: 27707929
pmcid: 5126373
doi: 10.1128/JVI.01254-16
Lu, J. et al. The IFITM proteins inhibit HIV-1 infection. J. Virol. 85, 2126–2137 (2011).
pubmed: 21177806
doi: 10.1128/JVI.01531-10
Zhou, B. et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J. Virol. 83, 10309–10313 (2009).
pubmed: 19605485
pmcid: 2748056
doi: 10.1128/JVI.01109-09